Pulse Biosciences Incの債務/株式は0.33です。
負債比率は、株主資本と企業資産の融資に使用される負債の相対的割合を示す財務比率です。
The debt to equity ratio is generally calculated by dividing debt by equity. The D/E ratio is also known as risk, gearing or leverage. The two components are often taken from the firm's balance sheet or statement of financial position (so-called book value), but the ratio may also be calculated using market values for both, if the company's debt and equity are publicly traded, or using a combination of book value for debt and market value for equity financially. Preferred stock can be considered part of debt or equity. Attributing preferred shares to one or the other is partially a subjective decision but will also take into account the specific features of the preferred shares. When used to calculate a company's financial leverage, the debt usually includes only the long-term debt.
pulse biosciences, inc. is a clinical stage electroceutical, an electrical energy based therapeutic, company pursuing commercial applications of its proprietary nano-pulse stimulation (nps) technology. nps is a non-thermal, drug-free energy-based technology that can stimulate unique behaviors in cells by applying ultra-short nanosecond (billionths of a second) electrical pulses that affect the cell membrane and intracellular structures. these cell effects influence cell regulation functions and can lead to unique immune system responses. pulse biosciences is investigating a variety of applications for its nps technology that exploits its unique biologic effect, including immuno-oncology and dermatology. pulse biosciences, inc. (plse, nasdaq) corporate headquarters is located in hayward, ca. ~ our mission ~ to build a viable company that designs, produces, and commercializes nano-pulse technology to improve and extend the lives of patients to solve the needs of patients, physicians, and